Business Description
Edwards Lifesciences Corp
NAICS : 339113
SIC : 3842
ISIN : US28176E1082
Share Class Description:
WBO:EWLS: Ordinary SharesDescription
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.29 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | 0.38 | |||||
| Interest Coverage | 102.74 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 10.67 | |||||
| Beneish M-Score | -1.21 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.4 | |||||
| 3-Year EBITDA Growth Rate | 20.6 | |||||
| 3-Year EPS without NRI Growth Rate | 10.5 | |||||
| 3-Year FCF Growth Rate | 0.3 | |||||
| 3-Year Book Growth Rate | 14.7 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.8 | |||||
| 9-Day RSI | 64.99 | |||||
| 14-Day RSI | 64.55 | |||||
| 6-1 Month Momentum % | -20.25 | |||||
| 12-1 Month Momentum % | -1.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.46 | |||||
| Quick Ratio | 2.89 | |||||
| Cash Ratio | 2.29 | |||||
| Days Inventory | 254.81 | |||||
| Days Sales Outstanding | 42.33 | |||||
| Days Payable | 44.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 1.3 | |||||
| Shareholder Yield % | 3.4 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.97 | |||||
| Operating Margin % | 27.4 | |||||
| Net Margin % | 63.02 | |||||
| FCF Margin % | 7.4 | |||||
| ROE % | 55.59 | |||||
| ROA % | 40.35 | |||||
| ROIC % | 22.84 | |||||
| ROC (Joel Greenblatt) % | 60.77 | |||||
| ROCE % | 18.91 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 10.8 | |||||
| Forward PE Ratio | 31.23 | |||||
| PE Ratio without NRI | 28.02 | |||||
| Shiller PE Ratio | 32.97 | |||||
| Price-to-Owner-Earnings | 12.05 | |||||
| PEG Ratio | 1.59 | |||||
| PS Ratio | 6.85 | |||||
| PB Ratio | 4.62 | |||||
| Price-to-Tangible-Book | 6.26 | |||||
| Price-to-Free-Cash-Flow | 91.79 | |||||
| Price-to-Operating-Cash-Flow | 55.87 | |||||
| EV-to-EBIT | 23.86 | |||||
| EV-to-Forward-EBIT | 25.73 | |||||
| EV-to-EBITDA | 21.93 | |||||
| EV-to-Forward-EBITDA | 23.1 | |||||
| EV-to-Revenue | 6.13 | |||||
| EV-to-Forward-Revenue | 6.91 | |||||
| EV-to-FCF | 82.53 | |||||
| Price-to-Projected-FCF | 2.15 | |||||
| Price-to-DCF (Earnings Based) | 1.04 | |||||
| Price-to-DCF (FCF Based) | 7.04 | |||||
| Price-to-Median-PS-Value | 0.75 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.98 | |||||
| Price-to-Graham-Number | 2.78 | |||||
| Price-to-Net-Current-Asset-Value | 13.25 | |||||
| Price-to-Net-Cash | 42.94 | |||||
| Earnings Yield (Greenblatt) % | 4.19 | |||||
| FCF Yield % | 1.11 | |||||
| Forward Rate of Return (Yacktman) % | 15.94 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Edwards Lifesciences Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 6,051.679 | ||
| EPS (TTM) (€) | 6.282 | ||
| Beta | 0.1 | ||
| Volatility % | 44.5 | ||
| 14-Day RSI | 64.55 | ||
| 14-Day ATR (€) | 1.12379 | ||
| 20-Day SMA (€) | 69.2065 | ||
| 12-1 Month Momentum % | -1.91 | ||
| 52-Week Range (€) | 54.5 - 88.28 | ||
| Shares Outstanding (Mil) | 589.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Edwards Lifesciences Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Edwards Lifesciences Corp Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Edwards Lifesciences Corp Frequently Asked Questions
What is Edwards Lifesciences Corp(WBO:EWLS)'s stock price today?
The current price of WBO:EWLS is €71.28. The 52 week high of WBO:EWLS is €88.28 and 52 week low is €54.50.
When is next earnings date of Edwards Lifesciences Corp(WBO:EWLS)?
The next earnings date of Edwards Lifesciences Corp(WBO:EWLS) is 2025-02-06 Est..
Does Edwards Lifesciences Corp(WBO:EWLS) pay dividends? If so, how much?
Edwards Lifesciences Corp(WBO:EWLS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers